Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP)

The safety of afatinib for the treatment of non-small cell lung cancer

(2016) Feliciano Barron et al.   Expert Opinion On Drug Safety

Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?

(2016) Mari Mino-Kenudson et al.   Cancer Biology & Medicine

EGFR: The Paradigm of an Oncogene-Driven Lung Cancer

(2015) G. J. Riely et al.   CLINICAL CANCER RESEARCH

Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma

(2015) Cheng Lin et al.   Clinical Lung Cancer

Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)

(2015) Oscar Arrieta et al.   Journal of Thoracic Oncology

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

(2015) Nan Chen et al.   Journal of Thoracic Oncology

The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer

(2015) Oscar Arrieta et al.   LUNG CANCER

Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the “Hispanic paradox”

(2015) Oscar Arrieta et al.   LUNG CANCER

Transformation to Small Cell Lung Cancer as an Acquired Resistance Mechanism in EGFR-mutant Lung Adenocarcinoma: A Case Report of Complete Response to Etoposide and Cisplatin

(2015) Ki-Eun Hwang et al.   TUMORI

Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors

(2015) Jéssica Gomes et al.   OncoTargets and Therapy

Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors

(2015) Qi Chen et al.   Oncotarget

The Evolution of Therapies in Non-Small Cell Lung Cancer

(2015) Vishal Boolell et al.   Cancers

Transformation to Small Cell Lung Cancer as an Acquired Resistance Mechanism in EGFR-mutant Lung Adenocarcinoma: A Case Report of Complete Response to Etoposide and Cisplatin

(2015) Ki-Eun Hwang et al.   TUMORI JOURNAL

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma

(2014) Yang Zhang et al.   OncoTargets and Therapy

Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA

(2014) D. A. Haber et al.   Cancer Discovery

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

(2013) Jae Cheol Lee et al.   Cancer Research and Treatment

Cost Effectiveness of Personalized Therapy for First-Line Treatment of Stage IV and Recurrent Incurable Adenocarcinoma of the Lung

(2012) Elizabeth A. Handorf et al.   Journal of Oncology Practice

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

(2010) Deric L. Wheeler et al.   Nature Reviews Clinical Oncology

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

(2009) David Jackman et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of the T Descriptors and Other Prognosis Factors in Pathologic Stage I Non-small Cell Lung Cancer in China

(2009) Ziming Li et al.   Journal of Thoracic Oncology